Stock comparison
Haemonetics
MannKind
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
HAE
Haemonetics
Market cap
$2.98B
Sector
Healthcare
MNKD
MannKind
Market cap
$1.04B
Sector
Healthcare
Overall winner
Haemonetics HAE
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | HAE | MNKD | Winner |
|---|---|---|---|
| Warren Buffett | 70B | 43D | HAE |
| Benjamin Graham | 85A | 23F | HAE |
| Philip Fisher | 60C | 59C | HAE |
| Peter Lynch | 54C | 60C | MNKD |
| Joel Greenblatt | 31F | 40D | MNKD |
| Charlie Munger | 54D | 48D | HAE |
| Terry Smith | 55D | 52D | HAE |
Side-by-side metrics
| Metric | HAE | MNKD |
|---|---|---|
| Market cap | $2.98B | $1.04B |
| P/E (TTM) | 24.8x | - |
| EV/EBIT | 14.1x | 36.6x |
| ROIC (TTM) | 8.37% | 1.8% |
| Gross margin | 55.74% | 75.96% |
| Net margin | 7.29% | -6.63% |
| Revenue CAGR 5y | 7.65% | 46.65% |
| EPS CAGR 5y | 24.62% | - |
| Debt / Equity | 1.5x | - |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
HAE leads on
- Net margin7.29%vs -6.63%+191%
- ROIC (TTM)8.37%vs 1.8%+78%
- Market cap$2.98Bvs $1.04B+65%
- EV/EBIT14.1xvs 36.6x+61%
MNKD leads on
- P/E (TTM)-vs 24.8x+157%
- Debt / Equity-vs 1.5x+121%
- Revenue CAGR 5y46.65%vs 7.65%+84%
- Gross margin75.96%vs 55.74%+27%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.